ArticleBMC women's health2025
Serum lactate dehydrogenase level in preeclampsia and its correlation with disease severity, maternal and perinatal outcomes.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Fibrinogen to Albumin Ratio, Lactate Dehydrogenase to Albumin Ratio and Uric Acid to Albumin Ratio in Preeclampsia.Journal of clinical medicine · 2025Article
- Prognostic value of antepartum LDH serum levels in predicting adverse maternal outcomes in hypertensive disorders of pregnancy: a prospective cohort study.BMC pregnancy and childbirth · 2025Article
- Review
- Pyroptosis as a therapeutic target in preeclampsia: current research and future directions.Frontiers in immunology · 2025Review
- Comparative analysis of lipid metabolism in trophoblast subpopulations in preeclampsia andFrontiers in molecular biosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia is a rapidly progressing pregnancy-specific multi-systemic syndrome that is the leading cause of maternal and neonatal morbidity and mortality. Lactate dehydrogenase (LDH) is a valuable and potential biomarker for predicting the severity of Preeclampsia.
objectivesTo assess the level of LDH in women with preeclampsia and to correlate its level with the severity of the disease and maternal/perinatal outcomes. PATIENTS AND
methodsThis prospective case-control study was conducted at Sulaimani Maternity Teaching Hospital, Sulaimaniyah, Iraq, from March 1st, 2021, to June 30th, 2022, on 150 pregnant women in 3rd trimester of their pregnancy. Patients (n = 100) were diagnosed with mild and severe Preeclampsia. Serum LDH level was measured and correlated with the severity of the disease and maternal/perinatal outcomes.
resultsLDH was significantly (p = 0.001) elevated in preeclampsia groups compared to the control group. The mild preeclampsia group had a mean LDH level of 302.9 ± 138.5 IU/L, while the severe preeclampsia group had a mean level of 488.6 ± 223.4 IU/L. Also, maternal complications, stillbirth rate, and neonatal intensive Care Unit (NICU) admission were higher in women with high LDH levels.
conclusionsThe serum LDH level is high in women with preeclampsia and correlated with the disease severity as well as maternal and perinatal outcomes. So, serum LDH may be a valuable biomarker for predicting the severity of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.